AU2015243379B2 - Tubulysin derivatives - Google Patents

Tubulysin derivatives Download PDF

Info

Publication number
AU2015243379B2
AU2015243379B2 AU2015243379A AU2015243379A AU2015243379B2 AU 2015243379 B2 AU2015243379 B2 AU 2015243379B2 AU 2015243379 A AU2015243379 A AU 2015243379A AU 2015243379 A AU2015243379 A AU 2015243379A AU 2015243379 B2 AU2015243379 B2 AU 2015243379B2
Authority
AU
Australia
Prior art keywords
cancer
mmol
compound
antibody
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015243379A
Other languages
English (en)
Other versions
AU2015243379A1 (en
Inventor
Lakshmaiah GINGIPALLI
Dorin Toader
Fengjiang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2015243379A1 publication Critical patent/AU2015243379A1/en
Application granted granted Critical
Publication of AU2015243379B2 publication Critical patent/AU2015243379B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015243379A 2014-04-11 2015-04-10 Tubulysin derivatives Ceased AU2015243379B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978460P 2014-04-11 2014-04-11
US61/978,460 2014-04-11
PCT/US2015/025235 WO2015157594A1 (en) 2014-04-11 2015-04-10 Tubulysin derivatives

Publications (2)

Publication Number Publication Date
AU2015243379A1 AU2015243379A1 (en) 2016-11-03
AU2015243379B2 true AU2015243379B2 (en) 2018-02-01

Family

ID=54264545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015243379A Ceased AU2015243379B2 (en) 2014-04-11 2015-04-10 Tubulysin derivatives

Country Status (19)

Country Link
US (2) US9427479B2 (enExample)
EP (1) EP3129362A4 (enExample)
JP (1) JP2017510661A (enExample)
KR (1) KR20160142392A (enExample)
CN (1) CN106458942A (enExample)
AR (1) AR100006A1 (enExample)
AU (1) AU2015243379B2 (enExample)
CA (1) CA2945318A1 (enExample)
CL (1) CL2016002548A1 (enExample)
EA (1) EA032203B1 (enExample)
IL (1) IL247822A0 (enExample)
MA (1) MA39862A (enExample)
MX (1) MX2016013373A (enExample)
NZ (1) NZ725131A (enExample)
PH (1) PH12016501995A1 (enExample)
SG (1) SG11201608203RA (enExample)
TW (1) TW201625662A (enExample)
UY (1) UY36075A (enExample)
WO (1) WO2015157594A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
TW201625662A (zh) * 2014-04-11 2016-07-16 麥迪紐有限責任公司 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物
PE20180355A1 (es) 2015-02-25 2018-02-21 Univ Rice William M Desacetoxitubulisina h y analogos de esta
HRP20200882T1 (hr) 2015-11-10 2020-09-04 Medimmune, Llc Vezujuće molekule specifične za asct2 i njihova uporaba
SG11201804268RA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3012960A1 (en) * 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
WO2019025983A1 (en) 2017-08-01 2019-02-07 Medimmune, Llc CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA
SG11202004801WA (en) 2017-12-31 2020-06-29 Hangzhou Dac Biotech Co Ltd A conjugate of a tubulysin analog with branched linkers
CN109456212A (zh) * 2018-12-03 2019-03-12 康化（上海）新药研发有限公司 一种沙库比曲中间体的合成方法
EP3898651A2 (en) 2018-12-21 2021-10-27 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
TWI753252B (zh) * 2019-05-03 2022-01-21 中國大陸商杭州多禧生物科技有限公司 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物
JP2022539076A (ja) * 2019-06-24 2022-09-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体
JP2023533218A (ja) * 2020-06-24 2023-08-02 レゲネロン ファーマシューティカルス，インコーポレーテッド ツブリシン及びタンパク質－ツブリシンコンジュゲート
IL301041A (en) 2020-09-11 2023-05-01 Medimmune Ltd Therapeutic B7-H4 binding molecules
CA3237211A1 (en) 2021-11-10 2023-05-19 Astrazeneca Ab Antibody molecules and conjugates
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US20080108820A1 (en) * 2002-03-22 2008-05-08 Campagna Silvio A Hemiasterlin Derivatives and Uses Thereof
WO2011017249A1 (en) * 2009-08-03 2011-02-10 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20130129753A1 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
US20130224228A1 (en) * 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
US8580820B2 (en) * 2009-07-22 2013-11-12 Kemtech S.R.L. Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof
US20140227295A1 (en) * 2013-02-14 2014-08-14 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2015157592A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
US9427479B2 (en) * 2014-04-11 2016-08-30 Medimmune Llc Tubulysin derivatives

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108820A1 (en) * 2002-03-22 2008-05-08 Campagna Silvio A Hemiasterlin Derivatives and Uses Thereof
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8580820B2 (en) * 2009-07-22 2013-11-12 Kemtech S.R.L. Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof
WO2011017249A1 (en) * 2009-08-03 2011-02-10 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20130197259A1 (en) * 2009-08-03 2013-08-01 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20130129753A1 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
US20130224228A1 (en) * 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
US20140227295A1 (en) * 2013-02-14 2014-08-14 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2015157592A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
US9427479B2 (en) * 2014-04-11 2016-08-30 Medimmune Llc Tubulysin derivatives

Also Published As

Publication number Publication date
MX2016013373A (es) 2017-05-02
KR20160142392A (ko) 2016-12-12
CA2945318A1 (en) 2015-10-15
NZ725131A (en) 2018-03-23
MA39862A (fr) 2017-02-15
EA201691963A1 (ru) 2017-06-30
TW201625662A (zh) 2016-07-16
EA032203B1 (ru) 2019-04-30
WO2015157594A1 (en) 2015-10-15
US9427479B2 (en) 2016-08-30
CN106458942A (zh) 2017-02-22
EP3129362A1 (en) 2017-02-15
CL2016002548A1 (es) 2017-02-24
AU2015243379A1 (en) 2016-11-03
EP3129362A4 (en) 2017-08-23
PH12016501995A1 (en) 2017-01-09
US20160339114A1 (en) 2016-11-24
JP2017510661A (ja) 2017-04-13
IL247822A0 (en) 2016-11-30
SG11201608203RA (en) 2016-10-28
US10159745B2 (en) 2018-12-25
UY36075A (es) 2015-10-30
AR100006A1 (es) 2016-08-31
US20150291657A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
AU2015243379B2 (en) Tubulysin derivatives
JP7138350B2 (ja) 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
EP4494657A1 (en) Exatecan derivative-antibody conjugate and medical use thereof
AU2016232839B2 (en) CD48 antibodies and conjugates thereof
AU2021266317A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
CA2991975C (en) Novel linkers and their uses in specific conjugation of drugs to a biological molecule
JP2023530128A (ja) 細胞結合分子とカンプトテシン類縁体との共役体
AU2024200147A1 (en) Exatecan derivatives, linker-payloads, and conjugates and thereof
EP4480499A1 (en) Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
KR20210106467A (ko) 튜불리신 및 단백질-튜불리신 접합체
KR20250131272A (ko) 신규 캄프토테신 유도체 및 그의 접합체
JP2023159139A (ja) 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
EP4527415A1 (en) Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
EP4623937A1 (en) Anti-tumor compound and use thereof
JP2024545138A (ja) 親和性が改善された抗体薬物複合体、その調製法、及びその応用
RU2852712C1 (ru) Конъюгированные с антителом химические индукторы расщепления brm и связанные с ними способы
US12415789B2 (en) Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers
AU2025267536A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
TW202508638A (zh) 連結子化合物及配體－藥物接合物、其製備方法及用途
NZ744940B2 (en) Conjugation linkers, antibody-drug conjugates thereof, and methods of synthesis and use of such conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired